跳至主要内容
临床试验/ISRCTN90497703
ISRCTN90497703已完成不适用

Antibiotic prophylaxis with 3-day course of prulifoxacin 600 mg in superficial bladder cancer patients undergoing Bacillus Calmette-Guerin (BCG) instillations: a prospective, randomised, open-label, controlled trial

Magna Graecia University of Catanzaro (UMG) (Italy)0 个研究点目标入组 70 人开始时间: 2008年7月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Both males and females, age older than 18
  • 2. Intermediate or high risk superficial bladder cancer
  • 3. Indication for BCG intravesical adjuvant therapy after transurethral resection (TUR)
  • 4. Signed informed consent

排除标准

  • 1. Patient age older than 85 years
  • 2. World Health Organization (WHO) performance status 3 or 4
  • 3. Previous treatment with BCG during the previous 3 months

研究者

发起方
Magna Graecia University of Catanzaro (UMG) (Italy)

相似试验